This FDA-approved product, co-developed by Mylan and Biocon Biologics, was unanimously recommended by the FDA Oncologic Drugs Advisory Committee
Mylan to offer Ogivri in both the 420mg and 150mg strengths, increasing access to treatment for thousands of HER2-positive breast and gastric cancer patients
PR Newswire
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Dec. 2, 2019
